

**Table 10.6i**  
**Immunosuppression Use for Antirejection Treatment from Transplant**  
**to One Year Following Transplantation, 1998 to 2007**  
**Recipients with Intestine Transplants**

	Year of Transplant									
	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>Transplants</b>	70	73	82	113	107	116	152	178	175	198
<b>Tx with Antirejection Treatments</b>	24	34	45	41	48	66	59	58	61	57
<b>Antibodies</b>										
Any in Category	20.8%	47.1%	48.9%	36.6%	31.3%	37.9%	45.8%	39.7%	63.9%	64.9%
Atgam/NRATG/NRATS	4.2%	0.0%	0.0%	2.4%	2.1%	0.0%	3.4%	3.4%	1.6%	3.5%
OKT3	12.5%	44.1%	31.1%	34.1%	27.1%	27.3%	33.9%	22.4%	41.0%	52.6%
Thymoglobulin	0.0%	11.8%	17.8%	7.3%	6.3%	3.0%	13.6%	10.3%	14.8%	12.3%
Zenapax	4.2%	5.9%	6.7%	0.0%	2.1%	1.5%	1.7%	3.4%	3.3%	12.3%
Simulect	0.0%	0.0%	6.7%	0.0%	0.0%	0.0%	0.0%	0.0%	1.6%	0.0%
Campath	0.0%	0.0%	0.0%	0.0%	8.3%	15.2%	6.8%	3.4%	8.2%	3.5%
<b>Corticosteroids</b>										
Any in Category	91.7%	85.3%	75.6%	80.5%	95.8%	92.4%	93.2%	86.2%	82.0%	82.5%
Steroids	91.7%	85.3%	75.6%	80.5%	95.8%	92.4%	93.2%	86.2%	82.0%	82.5%
<b>Antimetabolites</b>										
Any in Category	0.0%	0.0%	0.0%	2.4%	0.0%	0.0%	0.0%	1.7%	0.0%	0.0%
Cytoxan	0.0%	0.0%	0.0%	2.4%	0.0%	0.0%	0.0%	1.7%	0.0%	0.0%
Methotrexate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.